查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401172

用于细胞和基因治疗的药物输送装置的全球市场：市场规模、占有率、趋势分析、机会和预测（2019-2029）

Cell and Gene Therapy Drug Delivery Devices Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product Type ; By Technology ; By Commercialized Drug ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球细胞和基因疗法药物输送设备市场规模预计在预测期内将增加一倍以上，到 2029 年将达到 253,700 美元。

由于专注于开发有效的治疗方法和输送设备来治疗和管理越来越多的慢性疾病，用于细胞和基因治疗的药物传输设备的全球市场正在蓬勃发展。

在最近的一项研究中，领先的策略咨询和市场研究公司 BlueWeave Consulting 预计 2022 年细胞和基因治疗药物输送市场规模将达到 99,970 美元。 BlueWeave估计，在2023-2029年的预测期内，用于细胞和基因治疗的药物输送设备的全球市场规模预计将以16.79%的复合年增长率显着增长，并于2029年达到253,690美元。全球细胞和基因治疗药物传输市场的主要成长动力是癌症和慢性病盛行率的增加、该领域投资的增加、对罕见疾病治疗方法创新的需求，其中包括药品研发成本的增加以及FDA核准和临床试验的数量增加。已经出现了几种基于细胞和基因的治疗方法，它们利用生物工程技术来增强免疫系统抵抗疾病的能力，同时维持周围组织的健康。例如，基于抗体的治疗方法可以透过加强 T 细胞与癌细胞的相互作用来提高 T 细胞的有效性。其他改进，例如增加 CAR-T 与癌细胞之间相互作用的复杂性，将有助于提高 T 细胞靶向癌症的能力并减少对正常细胞的伤害。人口高龄化的加剧，加上全球癌症和遗传疾病发生率的增加，预计将显着增加细胞和基因治疗市场对药物传递设备的需求。该公司在细胞和基因疗法以及相关药物输送设备的研发方面进行的大量投资也证明了该行业对进步的承诺。近年来各种遗传和慢性疾病临床试验的成长趋势预计将在预测期内推动细胞和基因治疗药物传输设备市场。然而，製造系统的高成本和缺乏标准处理方案预计将限制预测期内的整体市场成长。

机会－增加细胞和基因治疗的研发投资

细胞和基因治疗市场正在见证私人和公共投资的大量涌入。对治疗不足的病理进行创新治疗方法的吸引力正在透过私人投资、首次股票公开发行和企业资金筹措吸引大量资金。私人公司增加对生命科学研究和开发的投资有助于细胞和基因治疗资金的快速成长。值得注意的是，2010年至2021年基因治疗和细胞治疗的投资成长率分别为59%和63%，在预测期内对推动全球细胞和基因治疗药物输送设备市场发挥了关键作用。此外，各地区政府正在积极提高患者和医疗保健专业人员的意识，进一步推动全球细胞和基因治疗药物传输设备市场的成长。

COVID-19 对细胞和基因治疗药物输送设备全球市场的影响

COVID-19 大流行对全球细胞和基因治疗药物输送市场产生了负面影响。有多种因素导致了这种情况的恶化，包括製造和物流流程的中断，导致材料供应链变得非常复杂。大流行促使各临床中心暂停业务，以降低病毒暴露的风险。对于保质期短、需要在製造地和给药中心之间及时运输的细胞治疗药物来说，出货延误是一个挑战。儘管存在这些障碍，市场参与者仍将重点转向应对大流行相关的挑战，基因治疗公司积极参与 COVID-19 疫苗的研究和生产。这一转变导致了竞争非专利药（CGT）定价和报销的显着扩展。

细胞和基因治疗药物传递的全球市场 - 按成药

全球细胞和基因治疗药物输送市场按成药细分为 Luxturna、Kymriah、Yescarta、Zolgensma、Provenge 和 Strimvelis 部分。 Luxturna 部门在全球细胞和基因治疗药物传输设备市场上拥有最高的商业化药物占有率。以voretigene neparvovec-rzyl为代表的Luxturna是一种开创性的基因疗法，可直接针对导致视网膜营养不良的特定基因突变。它是第一个在美国核准直接给药的基因疗法药物，专注于治疗与已确定的双基因 RPE65 突变相关的视网膜营养不良。 Luxturna 的机制涉及使用改良的腺结合病毒作为载体，将 RPE65 基因的功能副本直接传递到视网膜细胞。这种创新方法可以恢復正常的蛋白质生产，并将光转化为视网膜中的电讯号，有效防止视力丧失。由于其突破性的特性以及在治疗某些遗传疾病方面的成功，Luxturna 引起了人们的关注，并在细胞和基因治疗药物输送设备市场占据了重要占有率。

全球细胞和基因治疗药物传输市场（按地区）

全球细胞和基因治疗药物递送市场的详细研究报告涵盖了北美、欧洲、亚太、拉丁美洲、中东和非洲五个关键地区的众多主要国家的市场。在该区域。北美地区在细胞和基因治疗药物传递的全球市场中占据最高占有率。该地区的主导地位是由于各种中小企业和大型企业集团之间不断加强合作，旨在开发价格实惠的优质药品。此外，神经退化性疾病的增加以及透过研究、诊断和合成生物学寻找遗传性疾病有效治疗方法的需求不断增长，也对该地区的市场成长做出了重大贡献。在该地区，美国预计将在预测年内呈现最快的市场成长。这是由于监管机构，例如在该国运营的生技药品评估与研究中心（CBER），专注于细胞和基因治疗的药物传输设备。 CBER 为研究人员和製造商的新产品开发提供科学和监管指导。

竞争形势

在全球细胞和基因治疗药物输送设备市场中运作的一些主要企业包括 Amgen Inc.、Bausch &Lomb Incorporated、Renova Therapeutics、Becton、Dickinson and Company、Bluebird bio-Inc.、Castle Creek Biosciences, Inc.、Helixmith Co. Ltd 、Kite Pharma Inc.、Kolon TissueGene, Inc.、Novartis AG、Orchard Therapeutics plc.、Pfizer Inc.。为了进一步增加市场占有率，这些公司正在寻求併购、合作、合资和许可协议。,并采取各种策略，例如新产品发布。

该报告的详细分析提供了有关全球细胞和基因治疗药物输送市场的成长潜力、未来趋势和统计数据的资讯。它还涵盖了推动市场总规模预测的因素。该报告承诺提供全球细胞和基因治疗药物输送市场的最新技术趋势以及行业见解，以帮助决策者做出适当的策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 研究框架

第 2 章执行摘要

第三章 全球细胞与基因治疗药物传递设备的市场洞察

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 慢性病盛行率增加
      • 临床试验数量增加
    • 抑制因素
      • 高成本製造系统
      • 缺乏标准治疗方案
    • 机会
      • 提高患者和医生的设备意识
      • 细胞和基因治疗投资快速成长
    • 任务
      • 缺乏熟练的专业人员
  • 科技进步/最新发展
  • 法律规范
  • 波特五力分析

第四章细胞和基因治疗药物输送装置的全球市场概述

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依产品类型
      • 视网膜下注射插管
      • 延长管
      • 静脉导管
      • 无菌胰岛素注射器
      • 预充式註射器
      • 点滴袋
    • 依技术
      • 微晶片技术
      • 奈米科技
      • 脂质奈米粒子
    • 透过成药
      • Luxturna
      • Kymriah
      • Yescarta
      • Zolgensma
      • Provenge
      • Strimvelis
    • 按最终用户
      • 製药和生物技术公司
      • 学术/研究机构
      • 医院/诊所
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第五章北美细胞与基因治疗药物传递设备市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依产品类型
    • 依技术
    • 透过成药
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第六章欧洲细胞与基因治疗药物传递设备市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依产品类型
    • 依技术
    • 透过成药
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 欧洲其他地区

第七章亚太细胞与基因治疗药物传递设备市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依产品类型
    • 依技术
    • 透过成药
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲/纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 其他亚太地区

第八章拉丁美洲细胞与基因治疗药物传输设备市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依产品类型
    • 依技术
    • 透过成药
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第九章中东和非洲细胞和基因治疗药物传输设备市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 依产品类型
    • 依技术
    • 透过成药
    • 按最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东/非洲

第10章竞争形势

  • 主要企业及其产品列表
  • 2022年全球细胞与基因治疗药物传递设备市场占有率分析
  • 透过管理参数进行竞争基准化分析
  • 主要策略发展（合併、收购、合作伙伴关係等）
简介目录
Product Code: BWC231042

Global Cell and Gene Therapy Drug Delivery Devices Market Size More Than Doubles During Forecast Period to Touch USD 253.7 Thousand by 2029

Global Cell and Gene Therapy Drug Delivery Devices Market is flourishing because of a growing focus on developing efficient therapies and delivery devices for the treatment and management of the increasing prevalence of chronic diseases.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Cell and Gene Therapy Drug Delivery Devices Market size at USD 99.97 thousand in 2022. During the forecast period between 2023 and 2029, BlueWeave expects Global Cell and Gene Therapy Drug Delivery Devices Market size to grow at a significant CAGR of 16.79% reaching a value of USD 253.69 thousand by 2029. Major growth drivers for the Global Cell and Gene Therapy Drug Delivery Devices Market include an increasing prevalence of cancer and chronic diseases, increasing investments in the sector, the imperative to innovate treatments for rare diseases, augmented research and development expenditure in biopharmaceuticals, and a rising number of FDA approvals and clinical trials. Several emerging approaches in cell and gene-based therapies leverage biological engineering to enhance the immune system's ability to combat diseases while preserving the health of surrounding tissues. For instance, antibody-based therapies can enhance the effectiveness of T-cells by intensifying their interactions with cancer cells. Other modifications, such as enhancing the complexity of CAR-T and cancer cell interactions, contribute to refining T-cells' ability to target cancer, thereby reducing harm to normal cells. The escalating aging population, coupled with a growing incidence of cancer cases and genetic disorders globally, is projected to result in a significantly increased demand for drug delivery devices within the cell and gene therapy market. Also, substantial investments by companies in the research and development of cell and gene therapies, along with associated drug delivery devices, underscore the industry's commitment to advancements. The upward trajectory of clinical trials for various genetic and chronic diseases in recent years is poised to propel the cell and gene therapy drug delivery devices market during the forecast period. However, high cost of manufacturing system and lack of standard therapy protocols are anticipated to restrain the overall market growth during the forecast period.

Opportunity - Increasing Investments in Cell Therapy and Gene Therapy R&D

The cell therapy and gene therapy market is witnessing a notable influx of both private and public investment. The appeal of innovative therapies addressing underserved medical conditions has attracted substantial capital through private investments, initial public offerings, and corporate funding. The increasing amount of investments by private players in life sciences R&D is contributing to the rapid growth in funding for cell therapy and gene therapy. Notably, the investment growth rates for gene therapy and cell therapy from 2010 to 2021 are 59% and 63%, respectively, indicating a significant role in advancing the global Cell & Gene Therapy Drug Delivery Devices Market during the forecast period. Additionally, various governments across the regions are actively promoting awareness among patients and healthcare professionals, further fostering the growth of the Global Cell & Gene Therapy Drug Delivery Devices Market.

Impact of COVID-19 on Global Cell and Gene Therapy Drug Delivery Devices Market

COVID-19 pandemic adversely affected the Global Cell and Gene Therapy Drug Delivery Devices Market. Several factors contributed to this exacerbation, including disruptions in manufacturing and logistics processes, leading to significant complexities in the supply chain of materials. The pandemic prompted the suspension of operations at various clinical centers to mitigate the risk of virus exposure. Shipment delays posed challenges for cell therapies with short shelf lives, requiring timely transportation between manufacturing sites and administration centers. Despite these obstacles, market players shifted their focus to addressing pandemic-related challenges, with gene therapy companies actively engaging in COVID-19 vaccine research and manufacturing. This pivot resulted in significant expansions in prices and reimbursements for Competitive Generic Therapy (CGTs).

Global Cell and Gene Therapy Drug Delivery Devices Market - By Commercialized Drugs

Based on commercialized drugs, the Global Cell and Gene Therapy Drug Delivery Devices Market is divided into Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis segments. The Luxturna segment holds the highest share in the Global Cell and Gene Therapy Drug Delivery Devices Market by commercialized drugs. Luxturna, represented by voretigene neparvovec-rzyl, is a pioneering gene therapy that directly addresses specific genetic mutations causing retinal dystrophy. It stands out as the first gene therapy approved in the United States for direct administration, focusing on treating confirmed biallelic RPE65 mutation-associated retinal dystrophy. Luxturna's mechanism involves delivering a functional copy of the RPE65 gene directly to retinal cells, utilizing a modified adeno-associated virus as a vector. This innovative approach restores the normal protein production, converting light into electrical signals in the retina and effectively addressing vision loss. Due to its groundbreaking nature and successful outcomes in treating a specific genetic disorder, Luxturna has gained prominence and secured a significant share in the market for cell and gene therapy drug delivery devices.

Global Cell and Gene Therapy Drug Delivery Devices Market - By Region

The in-depth research report on the Global Cell and Gene Therapy Drug Delivery Devices Market covers the market in a number of key countries across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America region holds the highest share in the Global Cell and Gene Therapy Drug Delivery Devices Market. The region's dominance is attributed to the increasing collaborations between various small and medium enterprises and large conglomerates, aiming to develop affordable and high-quality medicines. Also, the rising occurrences of neurodegenerative issues and the growing demand for finding effective treatments for gene disorders through research, diagnostics, and synthetic biology are significant contributors to the regional market's growth. Within the region, the United States is expected to exhibit the fastest market growth in the forecast years. This is attributed to regulatory bodies like the Centre for Biologics Evaluation & Research (CBER) operating in the country, focusing on cell and gene therapy devices. The CBER provides scientific and regulatory guidance to researchers and manufacturers for the development of new products.

Competitive Landscape

Major players operating in the Global Cell and Gene Therapy Drug Delivery Devices Market include Amgen Inc., Bausch & Lomb Incorporated, Renova Therapeutics, Becton, Dickinson and Company, Bluebird bio-Inc., Castle Creek Biosciences, Inc., Helixmith Co. Ltd, Kite Pharma Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., and Pfizer Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Cell and Gene Therapy Drug Delivery Devices Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Cell and Gene Therapy Drug Delivery Devices Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Cell and Gene Therapy Drug Delivery Devices Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Rising number of clinical trials
    • 3.2.2. Restraints
      • 3.2.2.1. High cost of manufacturing system
      • 3.2.2.2. Lack of standard therapy protocols
    • 3.2.3. Opportunities
      • 3.2.3.1. Increasing awareness about the devices among patients and doctors
      • 3.2.3.2. Rapid growth in investment in cell therapy and gene therapy
    • 3.2.4. Challenges
      • 3.2.4.1. Shortage of skilled professionals
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Cell and Gene Therapy Drug Delivery Devices Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Thousand)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Product Type
      • 4.2.1.1. Subretinal Injection Cannula
      • 4.2.1.2. Extension Tube
      • 4.2.1.3. Intravenous Catheter
      • 4.2.1.4. Sterile Insulin Syringe
      • 4.2.1.5. Pre-Filled Syringe
      • 4.2.1.6. Infusion Bags
    • 4.2.2. By Technology
      • 4.2.2.1. Microchip Technology
      • 4.2.2.2. Nanotechnology
      • 4.2.2.3. Lipid Nanoparticles
    • 4.2.3. By Commercialized Drugs
      • 4.2.3.1. Luxturna
      • 4.2.3.2. Kymriah
      • 4.2.3.3. Yescarta
      • 4.2.3.4. Zolgensma
      • 4.2.3.5. Provenge
      • 4.2.3.6. Strimvelis
    • 4.2.4. By End User
      • 4.2.4.1. Pharmaceuticals & Biotechnology Company
      • 4.2.4.2. Academic & Research Institute
      • 4.2.4.3. Hospitals & Clinics
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Cell and Gene Therapy Drug Delivery Devices Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Thousand)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
    • 5.2.2. By Technology
    • 5.2.3. By Commercialized Drugs
    • 5.2.4. By End User
    • 5.2.5. By Country
      • 5.2.5.1. United States
      • 5.2.5.1.1. By Product Type
      • 5.2.5.1.2. By Technology
      • 5.2.5.1.3. By Commercialized Drugs
      • 5.2.5.1.4. By End User
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Product Type
      • 5.2.5.2.2. By Technology
      • 5.2.5.2.3. By Commercialized Drugs
      • 5.2.5.2.4. By End User

6. Europe Cell and Gene Therapy Drug Delivery Devices Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Thousand)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Commercialized Drugs
    • 6.2.4. By End User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Product Type
      • 6.2.5.1.2. By Technology
      • 6.2.5.1.3. By Commercialized Drugs
      • 6.2.5.1.4. By End User
      • 6.2.5.2. United Kingdom
      • 6.2.5.2.1. By Product Type
      • 6.2.5.2.2. By Technology
      • 6.2.5.2.3. By Commercialized Drugs
      • 6.2.5.2.4. By End User
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Product Type
      • 6.2.5.3.2. By Technology
      • 6.2.5.3.3. By Commercialized Drugs
      • 6.2.5.3.4. By End User
      • 6.2.5.4. France
      • 6.2.5.4.1. By Product Type
      • 6.2.5.4.2. By Technology
      • 6.2.5.4.3. By Commercialized Drugs
      • 6.2.5.4.4. By End User
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Product Type
      • 6.2.5.5.2. By Technology
      • 6.2.5.5.3. By Commercialized Drugs
      • 6.2.5.5.4. By End User
      • 6.2.5.6. Belgium
      • 6.2.5.6.1. By Product Type
      • 6.2.5.6.2. By Technology
      • 6.2.5.6.3. By Commercialized Drugs
      • 6.2.5.6.4. By End User
      • 6.2.5.7. Russia
      • 6.2.5.7.1. By Product Type
      • 6.2.5.7.2. By Technology
      • 6.2.5.7.3. By Commercialized Drugs
      • 6.2.5.7.4. By End User
      • 6.2.5.8. The Netherlands
      • 6.2.5.8.1. By Product Type
      • 6.2.5.8.2. By Technology
      • 6.2.5.8.3. By Commercialized Drugs
      • 6.2.5.8.4. By End User
      • 6.2.5.9. Rest of Europe
      • 6.2.5.9.1. By Product Type
      • 6.2.5.9.2. By Technology
      • 6.2.5.9.3. By Commercialized Drugs
      • 6.2.5.9.4. By End User

7. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Thousand)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Commercialized Drugs
    • 7.2.4. By End User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Product Type
      • 7.2.5.1.2. By Technology
      • 7.2.5.1.3. By Commercialized Drugs
      • 7.2.5.1.4. By End User
      • 7.2.5.2. India
      • 7.2.5.2.1. By Product Type
      • 7.2.5.2.2. By Technology
      • 7.2.5.2.3. By Commercialized Drugs
      • 7.2.5.2.4. By End User
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Product Type
      • 7.2.5.3.2. By Technology
      • 7.2.5.3.3. By Commercialized Drugs
      • 7.2.5.3.4. By End User
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Product Type
      • 7.2.5.4.2. By Technology
      • 7.2.5.4.3. By Commercialized Drugs
      • 7.2.5.4.4. By End User
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Product Type
      • 7.2.5.5.2. By Technology
      • 7.2.5.5.3. By Commercialized Drugs
      • 7.2.5.5.4. By End User
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Product Type
      • 7.2.5.6.2. By Technology
      • 7.2.5.6.3. By Commercialized Drugs
      • 7.2.5.6.4. By End User
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Product Type
      • 7.2.5.7.2. By Technology
      • 7.2.5.7.3. By Commercialized Drugs
      • 7.2.5.7.4. By End User
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Product Type
      • 7.2.5.8.2. By Technology
      • 7.2.5.8.3. By Commercialized Drugs
      • 7.2.5.8.4. By End User
      • 7.2.5.9. Vietnam
      • 7.2.5.9.1. By Product Type
      • 7.2.5.9.2. By Technology
      • 7.2.5.9.3. By Commercialized Drugs
      • 7.2.5.9.4. By End User
      • 7.2.5.10. Rest of APAC
      • 7.2.5.10.1. By Product Type
      • 7.2.5.10.2. By Technology
      • 7.2.5.10.3. By Commercialized Drugs
      • 7.2.5.10.4. By End User

8. Latin America Cell and Gene Therapy Drug Delivery Devices Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Thousand)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Commercialized Drugs
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Product Type
      • 8.2.5.1.2. By Technology
      • 8.2.5.1.3. By Commercialized Drugs
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Product Type
      • 8.2.5.2.2. By Technology
      • 8.2.5.2.3. By Commercialized Drugs
      • 8.2.5.2.4. By End User
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Product Type
      • 8.2.5.3.2. By Technology
      • 8.2.5.3.3. By Commercialized Drugs
      • 8.2.5.3.4. By End User
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Product Type
      • 8.2.5.4.2. By Technology
      • 8.2.5.4.3. By Commercialized Drugs
      • 8.2.5.4.4. By End User
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Product Type
      • 8.2.5.5.2. By Technology
      • 8.2.5.5.3. By Commercialized Drugs
      • 8.2.5.5.4. By End User

9. Middle East & Africa Cell and Gene Therapy Drug Delivery Devices Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Thousand)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Commercialized Drugs
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Product Type
      • 9.2.5.1.2. By Technology
      • 9.2.5.1.3. By Commercialized Drugs
      • 9.2.5.1.4. By End User
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Product Type
      • 9.2.5.2.2. By Technology
      • 9.2.5.2.3. By Commercialized Drugs
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Product Type
      • 9.2.5.3.2. By Technology
      • 9.2.5.3.3. By Commercialized Drugs
      • 9.2.5.3.4. By End User
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Product Type
      • 9.2.5.4.2. By Technology
      • 9.2.5.4.3. By Commercialized Drugs
      • 9.2.5.4.4. By End User
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Product Type
      • 9.2.5.5.2. By Technology
      • 9.2.5.5.3. By Commercialized Drugs
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Product Type
      • 9.2.5.6.2. By Technology
      • 9.2.5.6.3. By Commercialized Drugs
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Product Type
      • 9.2.5.7.2. By Technology
      • 9.2.5.7.3. By Commercialized Drugs
      • 9.2.5.7.4. By End User
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Product Type
      • 9.2.5.8.2. By Technology
      • 9.2.5.8.3. By Commercialized Drugs
      • 9.2.5.8.4. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Cell and Gene Therapy Drug Delivery Devices Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)